Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q3 2016 (← Previous) (Next →)

Filing Date: Nov 2, 2016

Total Value ($000): $130,994 (100.0% shares, 0.0% debt)

Holdings (11)

— Juno Therapeutics 28.2%

Value ($000) $36,898 Shares 1,229,512 Est. Cost $52.22 Unrealized —

— Paratek Pharmaceuticals 25.8%

Value ($000) $33,831 Shares 2,600,410 Est. Cost $34.18 Unrealized —

— Egalet 16.8%

Value ($000) $21,992 Shares 2,889,926 Est. Cost $5.98 Unrealized —

— FibroGen 13.0%

Value ($000) $17,019 Shares 822,175 Est. Cost $27.34 Unrealized —

— Nabriva Therapeutics 6.2%

Value ($000) $8,079 Shares 1,145,890 Est. Cost $9.50 Unrealized —

— ESSA Pharma 3.6%

Value ($000) $4,667 Shares 1,696,969 Est. Cost $5.22 Unrealized —

— Pieris Pharmaceuticals 2.6%

Value ($000) $3,384 Shares 1,848,984 Est. Cost $1.83 Unrealized —

— Proteon Therapeutics 1.8%

Value ($000) $2,333 Shares 250,000 Est. Cost $10.40 Unrealized —

— Dicerna Pharmaceuticals 1.0%

Value ($000) $1,314 Shares 223,457 Est. Cost $16.47 Unrealized —

EDIT Editas Medicine 0.7%

Value ($000) $892 Shares 66,162 Est. Cost $26.29 Unrealized -22.1%

— CymaBay Therapeutics 0.4%

Value ($000) $585 Shares 301,477 Est. Cost $1.94 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Juno Therapeutics	1,229,512	$36,898	28.2%	$52.22	—	Common Stock	48205A109
—	Paratek Pharmaceuticals	2,600,410	$33,831	25.8%	$34.18	—	Common Stock	699374302
—	Egalet	2,889,926	$21,992	16.8%	$5.98	—	Common Stock	28226B104
—	FibroGen	822,175	$17,019	13.0%	$27.34	—	Common Stock	31572Q808
—	Nabriva Therapeutics	1,145,890	$8,079	6.2%	$9.50	—	Sponsored ADR	62957M104
—	ESSA Pharma	1,696,969	$4,667	3.6%	$5.22	—	Common Stock	29668H104
—	Pieris Pharmaceuticals	1,848,984	$3,384	2.6%	$1.83	—	Common Stock	720795103
—	Proteon Therapeutics	250,000	$2,333	1.8%	$10.40	—	Common Stock	74371L109
—	Dicerna Pharmaceuticals	223,457	$1,314	1.0%	$16.47	—	Common Stock	253031108
EDIT	Editas Medicine	66,162	$892	0.7%	$26.29	-22.1%	Common Stock	28106W103
—	CymaBay Therapeutics	301,477	$585	0.4%	$1.94	—	Common Stock	23257D103